Novo Nordisk’s next-gen obesity drug underperforms in trial
Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell ...
Tag: Novo
Novo Holdings set to close $16.5 billion Catalent deal
Novo Holdings, the parent company of Novo Nordisk, can proceed with its planned $16.5 billion acquisition of Catalent, a leading ...
Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test
The battle for market share between the two leaders in the booming obesity drug sector has a new data point ...
Novo Nordisk, Zepbound, Orexo, Arrakis
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings
The blockbuster Novo Nordisk obesity drug Wegovy has met the main goals of a pivotal test in metabolic dysfunction steatohepatitis, ...
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!